Medicine and Dentistry
Thromboplastin
100%
Nitric Oxide
72%
Nuclear Factor
45%
Alternative Complement Pathway C3 C5 Convertase
45%
Messenger RNA
36%
Aortic Smooth Muscle Cell
36%
Antigen
27%
Study Design
27%
Steady State
18%
Binding Affinity
18%
Adenovirus Vector
18%
Pyrrolidine Dithiocarbamate
18%
Therapeutic Procedure
18%
Mutant
18%
Immunohistochemistry
9%
Gel Mobility Shift Assay
9%
Inducible Nitric Oxide Synthase
9%
Upregulation
9%
Northern Blotting
9%
Infection
9%
Smooth Muscle Cell
9%
Vascular Smooth Muscle Cell
9%
Synthetase
9%
Nitric Oxide Donor
9%
Analysis
9%
Assay
9%
Regulatory Mechanism
9%
INIS
tissues
100%
nitric oxide
90%
muscles
54%
rats
36%
messenger-rna
36%
antigens
27%
humans
18%
mutants
18%
vectors
18%
steady-state conditions
18%
pyrrolidines
18%
design
9%
levels
9%
regulations
9%
inhibition
9%
time dependence
9%
gels
9%
electrophoresis
9%
concentration
9%
mobility
9%
Pharmacology, Toxicology and Pharmaceutical Science
Thromboplastin
100%
Nitric Oxide
72%
Nuclear Factor
45%
Alternative Complement Pathway C3 C5 Convertase
45%
Messenger RNA
36%
Rat
36%
Antigen
27%
Adenovirus Vector
18%
S-Nitroso-N-Acetylpenicillamine
18%
Pyrrolidine Dithiocarbamate
18%
Infection
9%
Synthetase
9%
Inducible Nitric Oxide Synthase
9%
Nitric Oxide Donor
9%
Biochemistry, Genetics and Molecular Biology
Tissue Factor
100%
Nitric Oxide
81%
Messenger RNA
36%
Rat
36%
Steady State
18%
Binding Affinity
18%
Adenovirus Vector
18%
Pyrrolidine Dithiocarbamate
18%
S-Nitroso-N-Acetylpenicillamine
18%
Mutant
18%
Northern Blotting
9%
Upregulation
9%
Nitric Oxide Synthase
9%
Electrophoretic Mobility Shift Assay
9%
Time
9%
Regulatory Mechanism
9%
Nitric Oxide Synthase
9%